Therapeutic medications against diabetes: What we have and what we expect

被引:50
|
作者
Hu, Cheng [1 ,2 ]
Jia, Weiping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Shanghai Diabet Inst,Shanghai Key Lab Diabet Mell, 600 Yishan Rd, Shanghai 200233, Peoples R China
[2] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, South Campus,6600 Nanfeng Rd, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetes; Treatment; Drug delivery; Natural product; GLUCAGON-LIKE PEPTIDE-1; COTRANSPORTER; 2; INHIBITORS; ENCAPSULATES SUBCUTANEOUS IMPLANTS; INADEQUATE GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; BLOOD-GLUCOSE CONCENTRATION; GLP-1 RECEPTOR AGONISTS; BETA-CELL FUNCTION; ORAL DELIVERY; INSULIN DELIVERY;
D O I
10.1016/j.addr.2018.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related complications. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidiabetic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes control, with its greater efficiency, increased bioavailability, decreased toxicity and reduced dosing frequency. Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great potential in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. Our paper aim to overview these therapeutic methods for diabetes therapy. Proper combinations of these existing anti diabetic medications and searching for novel routes are both necessary for better diabetes control. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 50 条
  • [1] Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
    Ashwini Kumar
    Sudhanshu Kumar Bharti
    Awanish Kumar
    Pharmacological Reports, 2017, 69 : 959 - 970
  • [2] Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
    Kumar, Ashwini
    Bharti, Sudhanshu Kumar
    Kumar, Awanish
    PHARMACOLOGICAL REPORTS, 2017, 69 (05) : 959 - 970
  • [3] What did we expect? What have we reached?
    Steenfeldt-Foss, O
    NORDIC JOURNAL OF PSYCHIATRY, 1998, 52 : 59 - 60
  • [4] Artificial Intelligence in Urooncology: What We Have and What We Expect
    Fron, Anita
    Semianiuk, Alina
    Lazuk, Uladzimir
    Ptaszkowski, Kuba
    Siennicka, Agnieszka
    Leminski, Artur
    Krajewski, Wojciech
    Szydelko, Tomasz
    Malkiewicz, Bartosz
    CANCERS, 2023, 15 (17)
  • [5] VCSELs in '98: What we have and what we can expect
    Coldren, LA
    Hegblom, ER
    Akulova, YA
    Ko, J
    Strzelecka, EM
    Hu, SY
    VERTICAL-CAVITY SURFACE-EMITTING LASERS II, 1998, 3286 : 2 - 16
  • [6] Training in diabetes therapeutic education: what do we have and what do we lack?
    Yoldi, Carmen
    AVANCES EN DIABETOLOGIA, 2011, 27 (03): : 100 - 105
  • [7] The Fontan circulation: What have we learned? What to expect?
    de Leval, MR
    PEDIATRIC CARDIOLOGY, 1998, 19 (04) : 316 - 320
  • [8] The Fontan Circulation: What Have We Learned? What to Expect?
    M.R. de Leval
    Pediatric Cardiology, 1998, 19 : 316 - 320
  • [9] What are We and What do we Expect to Become?
    Angulo, J. C.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 279 - 279
  • [10] Five decades of Fontan palliation: What have we learned? What should we expect?
    Hassan, Adil
    Chegondi, Madhuradhar
    Porayette, Prashob
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (10)